Curanex Pharmaceuticals Inc
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$4.2M
- Total assets
- $11.6M
- Market cap
- $8.6M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $8.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 26, 2025
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Curanex Pharmaceuticals Inc.
